Clareo Health | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
PRIMARY OBJECTIVE:
I. Evaluate if the application of eutectic mixture of local anesthetics (EMLA) topical cream (2.5% lidocaine mixed with 2.5% prilocaine) prior to intra-dermal Technetium 99 sulfur colloid (Tc99 injection) for lymphoscintigraphy can improve associated pain.
OUTLINE: Patients are randomized to 1 of 2 cohorts.
COHORT 1: Patients apply EMLA cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.
COHORT 2: Patients apply placebo cream topically to skin 30 minutes prior to Tc99 lymphoscintigraphy procedure.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Biologic males or females
18 - 99 years of age
Histologically confirmed cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or other cutaneous malignancy for which lymphoscintigraphy and sentinel lymph node biopsy has been recommended.
You may not be if
Known allergy or intolerance to EMLA cream, lidocaine, prilocaine, or any other local anesthetic
History of adhesive allergy
Contraindication to Tc99 injection for sentinel lymph node mapping
Incarcerated patients
Patients incapable of independently providing consent
Mucosal or genital lymphoscintigraphy site
Pregnancy
Participant self-declared or Ohio State University (OSU) medical chart listing chronic pain as a pre-existing diagnosis
Participants with chronic pain as defined by the Centers for Disease Control and Prevention (CDC):"pain lasting 3 months or more that can be caused by a disease or condition, injury, medical treatment, or unknown reason" excluding those with stable co-morbid conditions such as peripheral neuropathy, fibromyalgia, arthritis, and cancer-related pain who do not require narcotics. Patients who require narcotics at any time within the 7-day period leading up to the procedure
